Cancer Drug Resistance

1. Biochemical Resistance

   1. Regulation of the Cellular Pharmacology and Cytotoxicity of Cisplatin by Copper Transporters

      • Roohangiz Safaei, Stephen B. Howell

      Pages 309-327

   2. Resistance To Taxanes

      • Lee M. Greenberger, Deepak Sampath

      Pages 329-358

   3. CpG Island Methylation and Drug Resistance

      • Jens M. Teodoridis, Robert Brown

      Pages 359-375

   4. De Novo and Acquired Resistance to Antitumor Alkylating Agents

      • Lori A. Hazlehurst, William S. Dalton

      Pages 377-389

   5. Resistance to Antiangiogenic Agents

      • George W. Sledge Jr., Kathy D. Miller, Bryan Schneider, Christopher J. Sweeney

      Pages 391-410

2. The Role of Hormones, Growth Factors, and Oncogenes

   1. Front Matter

      Pages 411-411

      PDF

   2. Resistance to Antiestrogens

      • Clodia Osipo, Ruth M. O’Regan

      Pages 413-433

   3. Mechanisms of Glucocorticoid Actions and Resistance in Multiple Myeloma

      • Varsha Gandhi, Beatriz Sanchez-Vega

      Pages 435-458

   4. Herceptin Resistance

      • Ingrid A. Mayer, Carlos L. Arteaga

      Pages 459-467

   5. Role of TGF-β in Tumor Progression and Metastasis

      • Jan Pinkas, Beverly A. Teicher

      Pages 469-489

   6. p53-Based Immunotherapy of Cancer

      • Albert B. DeLeo

      Pages 491-505

   7. Response and Resistance to Ionizing Radiation

      • Paul Dent, Adly Yacoub, Michael P. Hagan, Steven Grant

      Pages 507-529

   8. Amplification in DNA Copy Numbers as a Mechanism of Acquired Drug Resistance

      • M. Jim Yen, Ie-Ming Shih, Victor E. Velculescu, Tian-Li Wang

      Pages 531-540

3. Clinical Aspects of Resistance

   1. Front Matter

      Pages 541-541

      PDF

   2. Cancer Chemotherapy

      • Mika A. Sovak, David R. Spriggs

      Pages 543-557

   3. Molecular Profiling in Breast Cancer

      • Kristin Kee, Jeffrey E. Green

      Pages 559-576

   4. Tumor Immune Escape Mechanisms

      • Yi Ting Koh, M. Luz García-Hernández, W. Martin Kast

      Pages 577-602

4. Back Matter

   Pages 603-617

   PDF

Leading experts summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to anticancer drugs, and suggest new approaches to preventing and overcoming it. The authors review physiological resistance based upon tumor architecture, cellular resistance based on drug transport, epigenetic changes that neutralize or bypass drug cytotoxicity, and genetic changes that alter drug target molecules by decreasing or eliminating drug binding and efficacy. Highlights include new insights into resistance to antiangiogenic therapies, oncogenes and tumor suppressor genes in therapeutic resistance, cancer stem cells, and the development of more effective therapies. There are also new findings on tumor immune escape mechanisms, gene amplification in drug resistance, the molecular determinants of multidrug resistance, and resistance to taxanes and Herceptin.

• angiogenesis
• cancer
• cytotoxicity
• drug
• drug resistance
• hormones
• imaging
• immunotherapy
• leukemia
• melanoma
• oncogenes
• pharmacology
• resistance
• toxicity
• tumor

"...a resource to scientists of diverse specialties with interests relating to the repsonse of malignant disease to current and experimental therapies." - Neoplasma

"...an excellent book that is appropriate for scientists and clinicians with an interest in the basis of anticancer drug resistance." -Doody's Book Review, Weighted Numberical Score: 90 - 4 Stars!

• Genzyme Corporation, Framingham

  Beverly A. Teicher

Policies and ethics